Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label single-arm dose-escalation and dose-expansion study of SAR446268 in non-congenital myotonic dystrophy type 1
MOH_2025-11-19_015476Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Nov 2025
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SAR446268 in myotonic dystrophy type 1 (DM1), sponsored by Sanofi. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
SAR446268
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on MOH_2025-11-19_015476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-19_015476.